Patent · US Active

Formulations of PBMCs

US12150982B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

STEMCELL TECHNOLOGIES CANADA INC. · CA

Inventors

Howard Bernstein · Cambridge, US
Scott LOUGHHEAD · Watertown, US
Matthew BOOTY · Cambridge, US
Kelan HLAVATY · Belmont, US
Tarek ABDELJAWAD · Concord, US
Maisam Dadgar · Cambridge, US
Jason Murray · Watertown, US
David Chirgwin · Watertown, US
Harry An · Watertown, US
Armon R. Sharei · Watertown, US

Key dates

Filing date	Dec 28, 2021
Grant date	Nov 26, 2024
Priority date	—
Expiry date	Dec 28, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/20034
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application provides formulations of modified peripheral blood mononuclear cells (PBMCs), wherein the formulation comprises: PBMCs comprising at least one antigen (e.g., a human papillomavirus (HPV) antigen) and a cryopreservation medium. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.